FINWIRES · TerminalLIVE
FINWIRES

ASX:COH

10 stories mentioning ASX:COHUpdated 6d ago

Every FINWIRES story that references ASX:COH, newest first.

Asia

Australian Shares Fall; Cochlear Confirms US Duty-Free Access for Hearing Implant Systems

Australian shares declined on Friday, as concerns over inflation rose after oil prices jumped above the $100-mark.The S&P/ASX 200 Index declined 0.75%, or by 66.70 points, to close at 8,772.30.Overnight, the Nasdaq Composite index on Wall Street fell 2.2%, the S&P 500 retreated 1.2%, and the Dow Jones declined 1%.Brent crude oil futures were trading over $100 per barrel, after jumping 7% overnight to a two-month high of $102 per barrel. The Iran-aligned Houthis struck Saudi Arabian tankers in the Red Sea even as shipping remains constricted in the Straits of Hormuz.US President Donald Trump threatened to escalate the conflict with Iran after the attacks in the Red Sea. The US administration is also said to intend to impose higher tariffs on 60 trading partners.On the domestic front, Australia's private sector expanded at its fastest pace in 2026 in July as new business returned to growth after four months; however, business confidence remained subdued despite easing cost pressures, according to a S&P Global survey. The Flash Australia PMI Composite Output Index rose to 52.6 in July from 50.4 in June, marking its highest level since the start of the year and indicating a second consecutive month of private sector growth.The Reserve Bank of Australia (RBA) is anticipated to hold interest rates steady at 4.35% in 2026 amid a slowing activity backdrop, despite elevated inflation risks, before beginning to cut rates from mid-2027, National Australia Bank (ASX:NAB) said.In company news, Cochlear (ASX:COH) said its hearing implant systems will continue to be imported into the US duty-free after the US Government's final Section 301 investigation findings retained the tariff classification covering duty-free entry for hearing implants.Newmont (ASX:NEM) reported second quarter adjusted net income of $2.10 per share, up from $1.43 a year earlier. Revenue for the three months ended June 30 was $6.12 billion, compared with $5.32 billion a year earlier.Lastly, ASX (ASX:ASX) said Chief Financial Officer Andrew Tobin informed the group of his intention to retire.

ASX 200ASX:ASXASX:COHASX:NEM
Asia

Cochlear Confirms US Duty-Free Access for Hearing Implant Systems

Cochlear (ASX:COH) said its hearing implant systems will continue to be imported into the US duty-free after the US Government's final Section 301 investigation findings retained the tariff classification covering duty-free entry for hearing implants, according to a Friday filing with the Australian bourse.The company said it will continue to monitor global tariff developments to support ongoing access to its implantable hearing solutions worldwide, per the filing.The company said it is addressing the growing need for cochlear implants by working with stakeholders to raise awareness, strengthen policy support, and expand access to hearing loss interventions, noting that only about 5% of eligible people currently receive implants, the filing added.

ASX:COH
Asia

Jefferies Downgrades Cochlear to Hold from Buy; Price Target is AU$128.40

Cochlear (ASX:COH) has an average rating of hold and mean price target of AU$127.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

ASX:COH
Asia

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:COHASX:CSLASX:RMD
Asia

Cochlear Needs to Keep Promoting Implants as Volume Delays Not Structural, Says Jefferies, Shares Up 4%

Cochlear's (ASX:COH) current volume delays are not structural as its volume opportunity for implants remains strong, Jefferies said in a Wednesday note.Jefferies said that US Medicare Advantage and commercial insurance providers require prior authorization for cochlear implantation procedures, which is causing delays in cochlear implant procedure volumes.Cochlear needs to continue promoting the benefits of cochlear implants while also expanding its advocacy programs to support patient access and awareness, the investment firm added.Jefferies kept a buy rating on Cochlear with a price target of AU$137.

ASX:COH
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Jarden Adjusts Cochlear's Price Target to AU$169 from AU$224, Keeps at Neutral

Cochlear (ASX:COH) has an average rating of overweight and mean price target of AU$166.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

ASX:COH
Asia

Cochlear's Guidance Cut 'Far Worse Than Anticipated,' Multiple Also at Risk, Jarden Says

Cochlear's (ASX:COH) cut to fiscal 2026 profit guidance "is far worse than anticipated," and the company's multiple is also at risk given its recent inability to provide reliable forecasts, Jarden said in a Wednesday note.The company downgraded its fiscal year 2026 underlying net profit outlook to between AU$290 million and AU$330 million, saying that trading conditions for its hearing implants in developed markets have been weaker than expected since January."The issue seems to be largely in the Cochlear implant segment with developed markets softening, Middle East disruption, industrial action in Spain and Italy impacting surgical capacity, and a Chinese reimbursement reduction," Jarden said.The lowering of the guidance has little to do with foreign exchange, as that headwind has seemingly improved slightly, the equity research firm said, adding that the outlook includes a number of additional costs, such as doubtful debts in the Middle East and cost restructuring.Additionally, a Nexa implant launch without new features and Cochlear's expectation of a price premium paved the way for ongoing competitive pressures, while channel checks indicate the price premium is not sticking, especially in the US, as there has been no adjustment to the reimbursement for the device, Jarden said.Jarden maintained a neutral rating on Cochlear with a share price target of AU$224.Shares of the company were down more than 39% in recent Wednesday trade.

ASX:COH
Asia

ASX Midday Sector Update: Consumer Staples Stocks Rise, Cochlear Weighs on Health Care

Consumer staples stock rose more than 1% to lead gainers in midday trading on Wednesday.Treasury Wine Estates (ASX:TWE) was advancing more than 16% after saying it will transition to a new regional operating model, effective Oct. 1, under which the company will have four regional divisions.On the flip side, health care stocks retreated over 5%, weighed down by a sharp decline for sector heavyweight Cochlear (ASX:COH).The company's shares plunged more than 39% after it downgraded its fiscal year 2026 underlying net profit guidance, saying that trading conditions for its hearing implants in developed markets have been weaker than anticipated since January.

ASX 200ASX:COHASX:TWE
Asia

Cochlear Says Trading Conditions for Implants Weaker Than Expected Since January; Shares Hit 10-Year Low

Cochlear (ASX:COH) said trading conditions for cochlear implants in developed markets have been weaker than anticipated since January, with uncertainty regarding fourth quarter sales from the Middle East due to ongoing conflict, according to a Wednesday filing with the Australian bourse.As a result, the company is downgrading its fiscal 2026 underlying net profit guidance to AU$290 million to AU$330 million, the filing said.The company had previously disclosed that it expected to be at the lower end of its underlying net profit guidance range of between AU$435 million and AU$460 million, per the filing.Shares fell 38% in morning trade Wednesday and earlier reached their lowest since March 2016.

ASX:COH

Track with the FINWIRES app suite